Compounded Semaglutide
GLP-1 receptor agonist for weight management and glycemic control. Available as subcutaneous injectable in multiple concentration vials for flexible dosing protocols.
Use Cases
- Weight management
- Type 2 diabetes management
- Appetite suppression
Available Forms
- Injectable (subcutaneous)
- Multiple concentration vials
Regulatory Status Semaglutide was removed from the FDA shortage list in February 2024. Compounding is subject to evolving FDA enforcement discretion. Veridian only partners with pharmacies operating under compliant pathways.